Cargando…
Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13)
Classical monoaminergic antidepressants show several disadvantages, such as protracted onset of therapeutic action. Conversely, the fast and sustained antidepressant effect of the N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine raises vast interest in understanding the role of the glutamat...
Autores principales: | Vasilescu, Andrei-Nicolae, Schweinfurth, Nina, Borgwardt, Stefan, Gass, Peter, Lang, Undine E, Inta, Dragos, Eckart, Sarah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384686/ https://www.ncbi.nlm.nih.gov/pubmed/28408831 http://dx.doi.org/10.2147/NDT.S119004 |
Ejemplares similares
-
The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant
por: Moskal, Joseph R., et al.
Publicado: (2017) -
Region-Specific Enhancement of c-fos Expression by Combined Treatment With NMDA Receptor Agonists and Antagonists With Antidepressant Potential
por: Vasilescu, Andrei-Nicolae, et al.
Publicado: (2022) -
Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects
por: Donello, John E, et al.
Publicado: (2018) -
BDNF Release and Signaling are Required for the Antidepressant Actions of GLYX-13
por: Kato, Taro, et al.
Publicado: (2017) -
GLYX-13 pretreatment ameliorates long-term isoflurane exposure-induced cognitive impairment in mice
por: Liu, Huan, et al.
Publicado: (2019)